GSK3 inhibitors and disease.
This review describes, briefly, the characteristics and regulation of glycogen synthase kinase 3 (GSK3) together with the role of GSK3 dysfunctions in different pathologies, and GSK3 as target for therapeutic treatment in different diseases. Several GSK3 inhibitors acting at different levels are described in this work, ranging from cations like lithium to small compounds developed by different pharmaceutical companies. Also, the use of specific interference RNA (iRNA) for the specific inhibition of the expression of the different GSK3 isoforms is discussed.
Hernández
Félix
F
Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Cantoblanco, Madrid, Spain.
Nido
Javier Díaz
JD
Avila
Jesús
J
Villanueva
Nieves
N
D000544:Alzheimer Disease / Q000188:drug therapy / Q000201:enzymology; D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D018020:Lithium Compounds / Q000494:pharmacology / Q000627:therapeutic use; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000201:enzymology*
D004791:Enzyme Inhibitors; D018020:Lithium Compounds; D038362:Glycogen Synthase Kinase 3